Rentschler Biopharma: A 50-year Legacy of Exceptional CDMO Expertise

Published on: 


Explore how Rentschler Biopharma duels biopharmaceutical innovation, spanning from pioneering biological products to cutting-edge cell and gene therapies

Benedikt von Braunmühl (CEO) and Federico Pollano (vice president of business development) at Rentschler Biopharma explain what sets their CDMO apart. Viewers will learn about:

  • What exceptional CDMO expertise means: 25% of all FDA approved biopharmaceuticals in 2023 were supported by the company
  • Rentschler Biopharma’s US offerings, as well as commercial and development expertise
  • How the company is leveraging its expertise in the field of gene therapy